# Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation

> **NCT04397796** · PHASE1 · TERMINATED · sponsor: **ImmunityBio, Inc.** · enrollment: 4 (actual)

## Conditions studied

- COVID

## Interventions

- **BIOLOGICAL:** BM-Allo.MSC
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04397796
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-03
- **Primary completion:** 2020-09-06
- **Final completion:** 2020-09-06
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04397796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04397796, "Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04397796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*